Literature DB >> 1990979

Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa.

E M Nutt1, D Jain, A B Lenny, L Schaffer, P K Siegl, C T Dunwiddie.   

Abstract

Antistasin (ATS) is a selective, tight-binding inhibitor of blood coagulation Factor Xa originally isolated from the salivary glands of the Mexican leech Haementeria officinalis. In order to provide sufficient quantities of ATS to further investigate the role of Factor Xa in blood coagulation, a recombinant version of ATS has been produced in an insect baculovirus host-vector system. In this study, we describe the purification and in vitro and in vivo characterization of a single recombinant antistasin (rATS) isoform. The purified protein constitutes a minor isoform relative to the more abundant ATS isoforms present in leech salivary gland extracts. In vitro, rATS inhibits purified human Factor Xa stoichiometrically, prolongs plasma-based clotting assays at nanomolar concentrations, and like native ATS, is cleaved at a single position by Factor Xa during the course of inhibition. An initial evaluation of the in vivo efficacy of rATS was addressed utilizing a rhesus monkey model of mild disseminated intravascular coagulation. rATS was shown to fully suppress thromboplastin-induced fibrinopeptide A generation in a dose-dependent fashion. The availability of rATS should provide a valuable tool for the critical evaluation of the specific role played by Factor Xa in coagulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990979     DOI: 10.1016/0003-9861(91)90325-d

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

1.  Downstream processing of insect cell cultures.

Authors:  A R Bernard; M Lusti-Narasimhan; K M Radford; R S Hale; E Sebille; P Graber
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  X-ray structure of antistasin at 1.9 A resolution and its modelled complex with blood coagulation factor Xa.

Authors:  R Lapatto; U Krengel; H A Schreuder; A Arkema; B de Boer; K H Kalk; W G Hol; P D Grootenhuis; J W Mulders; R Dijkema; H J Theunissen; B W Dijkstra
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

Review 3.  Novel inhibitors of factor X for use in cardiovascular diseases.

Authors:  F A Spencer; R C Becker
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

4.  Site-directed mutagenesis of the leech-derived factor Xa inhibitor antistasin. Probing of the reactive site.

Authors:  K J Hofmann; E M Nutt; C T Dunwiddie
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

Review 5.  Medicinal leech therapy-an overall perspective.

Authors:  Ali K Sig; Mustafa Guney; Aylin Uskudar Guclu; Erkan Ozmen
Journal:  Integr Med Res       Date:  2017-08-10

Review 6.  European Medicinal Leeches-New Roles in Modern Medicine.

Authors:  Sarah Lemke; Andreas Vilcinskas
Journal:  Biomedicines       Date:  2020-04-27

Review 7.  New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).

Authors:  Rick H van Gorp; Leon J Schurgers
Journal:  Nutrients       Date:  2015-11-17       Impact factor: 5.717

8.  Management of herpes zoster in Ayurveda through medicinal leeches and other composite Ayurveda Treatment.

Authors:  Amit Nakanekar; Punam Khobarkar; Sanjana Dhotkar
Journal:  J Ayurveda Integr Med       Date:  2020-08-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.